MRO Controversies

1 Hour 28 Minutes
SKU: 10ACOEM-2210

Track: Management and Administration in OEM

Karl Auerbach, MD, MBA, MS, FACOEM*, University of Rochester, Rochester, NY

Douglas W. Martin, MD, FAAFP, FAADEP, FACOEM*, St. Luke's Center for Occupational Health Excellence, Sioux City, IA
Donna R. Smith, PhD, FirstLab, Inc., North Wales, PA

In this session, common and not-so-common difficulties with federally regulated drug testing programs will be discussed and reviewed. The role of the MRO in audits conducted by the various Department of Transportation operating agencies will be covered. The duty of the MRO to report medications that may present a safety risk to the designated employer representative and Americans with Disabilities Act implications of these actions will be explored. We will also spend time discussing varying scenarios that arise in non-regulated testing. Real-life case scenarios will be presented that cover unusual or challenging issues for the MRO. This session concludes with a brief legislative update of any proposed regulatory changes that might affect the MRO. The target audience for this session is medical review officers and/or those involved with developing or overseeing employer drug and alcohol testing programs. This session is sponsored by the Medical Review Officers Special Interest Section.

Product speakers
Recently viewed products